Yingkai Cheng
Impact in
-
- HIV, Drug Use, Sexual Risk
- Substance Abuse Treatment and Outcomes
Papers in
-
- Lung Cancer Treatments and Mutations 3
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 2
- Oncology 3
- HER2/EGFR in Cancer Research 2
- Lung Cancer Research Studies 2
- Peptidase Inhibition and Analysis 1
- Co-authors
- Susan G. Sherman (2 shared papers)Alex H. Kral (1 shared paper)S. Hoog (1 shared paper)Sherie A. Dowsett (1 shared paper)Andreas Saltos (1 shared paper)Zenta Tsuchihashi (3 shared papers)Egbert F. Smit (4 shared papers)Misako Nagasaka (1 shared paper)
- Journals
- Journal of Clinical Oncology (3 papers)Cancer Research (2 papers)Investigative Radiology (1 paper)Harm Reduction Journal (1 paper)International Journal of Medical Sciences (1 paper)
- Partner nations
- United StatesJapanNetherlands
In The Last Decade
Yingkai Cheng
12 papers receiving 261 citations
Yingkai Cheng's Hit Papers
Peers
Comparison fields: 5 of 56
- Toxicology 13
- Epidemiology 108
- Public Health, Environmental and Occupational Health 90
- Oncology 82
- Pediatrics, Perinatology and Child Health 39
Countries citing papers authored by Yingkai Cheng
This map shows the geographic impact of Yingkai Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yingkai Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yingkai Cheng more than expected).
Fields of papers citing papers by Yingkai Cheng
This network shows the impact of papers produced by Yingkai Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yingkai Cheng. The network helps show where Yingkai Cheng may publish in the future.
Co-authors
The 25 scholars most cited alongside Yingkai Cheng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial Hit paper breakdown → | 2024 | 76 |
| 2 | 2006 | 70 | |
| 3 | 2006 | 40 | |
| 4 | 2013 | 27 | |
| 5 | 2013 | 15 | |
| 6 | 2018 | 15 | |
| 7 | 2023 | 7 | |
| 8 | 2024 | 6 | |
| 9 | 2024 | 4 | |
| 10 | 2018 | 4 | |
| 11 | 2016 | 2 | |
| 12 | 2025 | 1 | |
| 13 | 2025 | 0 |
About Yingkai Cheng
Yingkai Cheng is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Public Health, Environmental and Occupational Health, Pediatrics, Perinatology and Child Health and Epidemiology, having authored 13 papers that have together received 267 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (3 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers), Opioid Use Disorder Treatment (2 papers), HER2/EGFR in Cancer Research (2 papers), HIV, Drug Use, Sexual Risk (2 papers), Lung Cancer Research Studies (2 papers), Peptidase Inhibition and Analysis (1 paper) and Thyroid Disorders and Treatments (1 paper). The work is most often cited by research in Toxicology (13 citations), Epidemiology (108 citations), Public Health, Environmental and Occupational Health (90 citations), Oncology (82 citations) and Pediatrics, Perinatology and Child Health (39 citations). Yingkai Cheng has collaborated with scholars based in United States, Japan and Netherlands. Frequent co-authors include Susan G. Sherman, Alex H. Kral, S. Hoog, Sherie A. Dowsett, Andreas Saltos, Zenta Tsuchihashi, Egbert F. Smit, Misako Nagasaka, Pasi A. Jänne and Haruyasu Murakami. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Investigative Radiology, Harm Reduction Journal and International Journal of Medical Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.